What We're Reading: Page 246
Industry reads hand-picked by our editors
Apr 05, 2019
Apr 04, 2019
-
Bloomberg
Novartis CEO's $50 Billion of Deals Was Just the First Act
-
The Washington Post
FDA’s Gottlieb heads back to AEI to tackle drug prices
-
Financial Times
Some drug companies are still imposing triple-digit price rises
-
BioCentury
FDA's Pazdur encourages Chinese companies to bring low-cost PD-1 drugs to U.S. market
Apr 03, 2019
-
The New York Times
One Day There May Be a Drug to Turbocharge the Brain. Who Should Get It?
-
The Wall Street Journal
Generic-Drug Trends Squeeze Walgreens Profit
-
Healthcare Dive
Hospitals look to venture capital as R&D extension
-
California Healthline
Finding Homeless Patients A Place To Heal
Apr 02, 2019
-
Forbes
Sources: Martin Shkreli Thrown In Solitary Confinement After Claims He Ran Company From Prison
-
BioCentury
Pazdur grills PD-1/PD-L1 companies over lack of collaboration, trial redundancies
-
Kaiser Health News
Elite hospitals plunge into unproven stem cell treatments
-
STAT
Biotech's biggest companies open their labs to an unlikely inspector: a vet
Apr 01, 2019
-
The Wall Street Journal
OxyContin-Maker Owner Maligned Opioid Addicts, Suit Says
-
Quartz
The pharma industry has failed stroke, so doctors are looking elsewhere
-
Ars Technica
The true dollar cost of the anti-vaccine movement
-
Fast Company
This free AI reads X-rays as well as doctors
Mar 29, 2019
-
The New York Times
At 71, she's never felt pain or anxiety. Now scientists know why.
-
Science
New drugs that unleash the immune system on cancers may backfire, fueling tumor growth
-
San Francisco Business Times
Drug giant cutting 178 jobs, three years after buying Peninsula biotech for $6 billion
-
The Wall Street Journal
FDA commissioner calls for tighter standard for approval of new opioid drugs
Mar 28, 2019
-
Undark
The worrisome rise of direct-to-consumer medicine
-
Financial Times
Human gene editing is too transformative to be guided by the few
-
Axios
Marijuana, psychedelics get a second look from Big Pharma
-
San Francisco Business Times
Look who leased the top floors of South San Francisco's new biotech highrise
Previous
